The Ongoing Management of Hyperkalaemia in Chronic Kidney Disease Patients: Cases for Clinical Decisions

This educational symposium provided an insight into the most current clinical evidence of the efficacy and safety of renin—angiotensin—aldosterone system inhibitors (RAASis) for patients with chronic kidney disease (CKD). The programme provided an opportunity to discuss ways to optimise and maintain RAASis in this population by introducing CKD patient cases and the dilemmas of their clinical presentation, and novel treatment options, including benefits, harms, and potential consequences. Prof David C. Wheeler introduced the debate about the use of RAASis and the associated risk of hyperkalaemia in CKD patients. Prof Francesco Locatelli discussed the management of blood pressure (BP) in CKD and reviewed the most current guidelines for the prevention of hyperkalaemia in this population. Prof Adrian Covic presented the controversies around the use of RAASis in specific group populations. Survival, cardiovascular events (CVEs), and progression of CKD were the main points of his presentation. Finally, Prof David C. Wheeler discussed the latest research on novel therapies for the management of hyperkalaemia.